← Leaderboards
Derek Ronald Duckett
H. Lee Moffitt Cancer Ctr & Res Inst
$9,922,620
Attributed
$20,713,382
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,713,382 · 11
By mechanism
R01$18,530,335 · 8
RF1$1,878,085 · 1
P30$304,962 · 2
Top collaborators
- John L. Cleveland13 shared
- Thomas D Bannister10 shared
- Eric B. Haura8 shared
- Andrii Monastyrskyi8 shared
- Jun Qi4 shared
- Louis Daniel Scampavia3 shared
- William R Roush1 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- John L. Cleveland$27,832,236
- Susan T Vadaparampil$11,375,059
- Thomas D Bannister$24,896,252
- Stanislav Drapela$123,182
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeCellsPathway InteractionsMalignant NeoplasmsBiochemicalSignal TransductionPharmaceutical PreparationsDesignPlayStructureResistanceResponseLeadBaseProgramsNovel TherapeuticsTumorIn VivoDoseDrug KineticsMolecular ProbesPreventGenetic TranscriptionReporter
Grant awards (43)
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$681,912
R01 · FY2025 · CA · contact PI
Molecular Medicine$47,591
P30 · FY2025 · CA · contact PI
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$649,046
R01 · FY2024 · CA · contact PI
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$472,337
R01 · FY2024 · CA · contact PI
Molecular Medicine$47,589
P30 · FY2024 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$714,894
R01 · FY2023 · CA · contact PI
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$700,051
R01 · FY2023 · CA · contact PI
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$666,289
R01 · FY2023 · CA · contact PI
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$487,253
R01 · FY2023 · CA · contact PI
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$72,662
R01 · FY2023 · CA · contact PI
Molecular Medicine$47,588
P30 · FY2023 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$714,896
R01 · FY2022 · CA · contact PI
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$700,051
R01 · FY2022 · CA · contact PI
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$666,846
R01 · FY2022 · CA · contact PI
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$487,253
R01 · FY2022 · CA · contact PI
Molecular Medicine$162,194
P30 · FY2022 · CA · contact PI
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$74,145
R01 · FY2022 · CA · contact PI
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$29,208
R01 · FY2022 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$729,483
R01 · FY2021 · CA · contact PI
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$714,336
R01 · FY2021 · CA · contact PI
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$679,205
R01 · FY2021 · CA · contact PI
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma$497,197
R01 · FY2021 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$729,484
R01 · FY2020 · CA · contact PI
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$714,336
R01 · FY2020 · CA · contact PI
Development of in vivo active small molecule selective inhibitors of ASK1$457,122
R01 · FY2019 · GM · contact PI
Development of in vivo active small molecule activators of Ulk1$1,878,085
RF1 · FY2018 · AG · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$678,459
R01 · FY2018 · CA · contact PI
Development of in vivo active small molecule selective inhibitors of ASK1$518,828
R01 · FY2018 · GM · contact PI
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$470,637
R01 · FY2018 · CA · contact PI
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$298,954
R01 · FY2018 · CA · contact PI
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer$106,378
R01 · FY2018 · CA · contact PI
Development of in vivo active small molecule selective inhibitors of ASK1$71,929
R01 · FY2018 · GM · contact PI
Development of in vivo active small molecule selective inhibitors of ASK1$598,284
R01 · FY2017 · GM · contact PI
High Throughput Screening to Discover Ulk1 Kinase Inhibitors$453,082
R01 · FY2017 · GM · contact PI
High Throughput Screening to Discover Ulk1 Kinase Inhibitors$453,082
R01 · FY2016 · GM · contact PI
High Throughput Screening to Discover Ulk1 Kinase Inhibitors$621,865
R01 · FY2015 · GM · contact PI
High Throughput Screening to Discover Chemical Probes of ASK1$381,228
R01 · FY2015 · GM · contact PI
High Throughput Screening to Discover Chemical Probes of ASK1$381,842
R01 · FY2014 · GM · contact PI
High-throughput assay development for molecular probes targeting the ULK1 kinase$340,000
R01 · FY2014 · CA
High-throughput assay development for molecular probes targeting the ULK1 kinase$139,293
R01 · FY2014 · CA
High-throughput assay development for molecular probes targeting the ULK1 kinase$464,470
R01 · FY2013 · CA
High Throughput Screening to Discover Chemical Probes of ASK1$436,923
R01 · FY2013 · GM · contact PI
High-throughput assay development for molecular probes targeting the ULK1 kinase$477,075
R01 · FY2012 · CA